Fig. 8

SFRT potentiates immune mediated tumor clearance. A Average fold change of effector population in responding or non-responding mIHC slide 63 tumors treated with 2 Gy × 35 of WTRT, SFRT-GRID(30:70) or SFRT-GRID(50:50). B Distribution of clearance times for responding tumors in (A). C, D Contribution of effector-mediated cancer cell death, treatment, and apoptosis in the 7 day or 1 day leading up to and including clearance of tumors treated with SFRT-GRID(30:70). E, F Contribution of effector-mediated cancer cell death, treatment, and apoptosis in the 7 day or 1 day leading up to and including clearance of tumors treated with SFRT-GRID(50:50). Error bars are mean \(\pm\) SEM. (**p < 0.01, ***p < 0.001, two-sided Wilcoxon rank sum test, Table S8–S9)